Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

Investor Relations

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

Transfer Agent

Securities Transfer Corporation
2901 N. Dallas Parkway
Suite 380
Plano, Texas 75093
T: 469-633-0101
F: 469-633-0088
www.stctransfer.com